These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1941824)

  • 81. Functional asplenia and vasculitis associated with antineutrophil cytoplasmic antibodies.
    Sunder-Plassmann G; Geissler K; Penner E
    N Engl J Med; 1992 Aug; 327(6):437-8. PubMed ID: 1625731
    [No Abstract]   [Full Text] [Related]  

  • 82. Antineutrophil cytoplasmic antibodies.
    Thompson RA; Lee SS
    Lancet; 1989 Mar; 1(8639):670-1. PubMed ID: 2564483
    [No Abstract]   [Full Text] [Related]  

  • 83. Assessment of disease activity in systemic vasculitis.
    Tse WY; Cockwell P; Savage CO
    Postgrad Med J; 1998 Jan; 74(867):1-6. PubMed ID: 9538478
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Autoimmune disease in hairy-cell leukemia: systemic vasculitis and anticardiolipin syndrome.
    Salvarani C; Capozzoli N; Baricchi R; Macchioni PL; Rossi F; Ghirelli L; Bellelli A; Tumiati B; Portioli I
    Clin Exp Rheumatol; 1989; 7(3):329-30. PubMed ID: 2758712
    [No Abstract]   [Full Text] [Related]  

  • 85. Anti-neutrophil cytoplasm antibodies (ANCA) in a patient with the vasculitis of myelodysplasia.
    Savige JA; Smith C; Chang L; Duggan JC
    Br J Haematol; 1991 Aug; 78(4):583-4. PubMed ID: 1911357
    [No Abstract]   [Full Text] [Related]  

  • 86. [Anti-neutrophil cytoplasma antibodies and vasculitis].
    Chen Y; He XH
    Zhonghua Nei Ke Za Zhi; 1994 Oct; 33(10):707-9. PubMed ID: 7712920
    [No Abstract]   [Full Text] [Related]  

  • 87. Venostasis, subclinical vasculitis and von Willebrand factor antigen.
    Blann AD; Wainwright AC; Sheeran TP; Emery P
    Br J Rheumatol; 1991 Oct; 30(5):373-5. PubMed ID: 1913009
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody.
    Hall JB; Wadham BM; Wood CJ; Ashton V; Adam WR
    Aust N Z J Med; 1984 Jun; 14(3):277-8. PubMed ID: 6208890
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Antineutrophilic cytoplasmic antibodies in systemic vasculitis.
    MacIsaac AI; Davies DJ; Moran JE; Niall FJ; Murphy BF
    Mayo Clin Proc; 1990 Jan; 65(1):124-5. PubMed ID: 2296208
    [No Abstract]   [Full Text] [Related]  

  • 90. [Two children with suspected primary vasculitis of mesenteric vessels--a case report].
    Moli M; Tomono N; Ibe M; Nakajima S; Miyamae T; Yokota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2000 Apr; 23(2):148-55. PubMed ID: 10863331
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis.
    Holt CM; Lindsey N; Moult J; Malia RG; Greaves M; Hume A; Rowell NR; Hughes P
    Clin Exp Immunol; 1989 Dec; 78(3):359-65. PubMed ID: 2612050
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Plasma and serum von Willebrand factor antigen concentrations in connective tissue disorders.
    Blann AD; Hopkins J; Winkles J; Wainwright AC
    Ann Clin Biochem; 1992 Jan; 29 ( Pt 1)():67-71. PubMed ID: 1536529
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Screening test for anti-neutrophil cytoplasmic antibodies.
    Duursma J; Pudifin DJ
    S Afr Med J; 1993 Nov; 83(11):865, 867. PubMed ID: 7839233
    [No Abstract]   [Full Text] [Related]  

  • 94. Activation of endothelial cells in thrombosis and vasculitis.
    Cockwell P; Tse WY; Savage CO
    Scand J Rheumatol; 1997; 26(3):145-50. PubMed ID: 9225867
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Vasculitic syndromes associated with other rheumatic conditions and unclassified systemic vasculitis.
    Bacon PA
    Curr Opin Rheumatol; 1991 Feb; 3(1):56-61. PubMed ID: 2043452
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Identification of an autoantibody to vascular endothelial cell-specific antigens in patients with systemic vasculitis.
    Brasile L; Kremer JM; Clarke JL; Cerilli J
    Am J Med; 1989 Jul; 87(1):74-80. PubMed ID: 2741984
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Malignancy risk in vasculitis.
    Kermani TA; Warrington KJ; Amin S
    Ther Adv Musculoskelet Dis; 2011 Feb; 3(1):55-63. PubMed ID: 22870466
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Molecular diagnosis of collagen vascular diseases and vasculitides].
    Hoffmann K; Hertl M; Sitaru C
    Hautarzt; 2016 Jan; 67(1):40-52. PubMed ID: 26650868
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Von Willebrand factor: a possible biomarker for disease activity in vasculitis.
    Keret S; Mazareeb J; Snir A; Shouval A; Awisat A; Kaly L; Rosner I; Rozenbaum M; Boulman N; Hardak E; Slobodin G; Rimar D
    Scand J Rheumatol; 2024 Nov; 53(6):433-441. PubMed ID: 38314784
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Anti-endothelial cell antibodies: a need for standardization.
    Adler Y; Salozhin K; Le Tonqueze M; Shoenfeld Y; Youinou P
    Lupus; 1994 Apr; 3(2):77-84. PubMed ID: 7920618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.